Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pulmonx (LUNG) Shares Repurchased (2020 - 2022)

Pulmonx (LUNG) reported Shares Repurchased of $27000.0 for Q4 2022, up 3.85% on a QoQ basis from $26000.0 in Q1 2021.

Pulmonx (LUNG) has 3 years of Shares Repurchased data on file, last reported at $27000.0 in Q4 2022.

  • Quarterly Shares Repurchased changed N/A year-over-year to $27000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $27000.0 (up 3.85% YoY) and the FY2022 annual result came in at $27000.0, up 3.85% from the prior year.
  • Shares Repurchased grew to $27000.0 in Q4 2022 per LUNG's latest filing, from $26000.0 in the prior quarter.
  • Across five years, Shares Repurchased topped out at $27000.0 in Q4 2022 and bottomed at $21000.0 in Q3 2020.
  • The 3-year median for Shares Repurchased is $26000.0 (2021), against an average of $24666.7.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Repurchased (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 180.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 105.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 421.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 100.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 74.30 Mn
10 Pulmonx 67.30 Mn -2.45 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 27,000.00
Dec 31, 2022 27,000.00
Mar 31, 2021 26,000.00
Mar 31, 2021 26,000.00
Sep 30, 2020 21,000.00
Sep 30, 2020 21,000.00